Scarica l'app Stockscreener
0.00
100.00%
-1.71
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose enters equity distribution agreement with Piper Sandler and Canaccord Genuity - McCarthy Tétrault
Aptose Announces Results from Annual and Special Meeting of Shar - GuruFocus
Aptose Announces Results from Annual and Special Meeting of Shareholders - The Globe and Mail
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N - GuruFocus
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - The Manila Times
(APS) Advanced Equity Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
5.04%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):